UroGen Pharma Ltd. - 8-K Filing

UroGen Pharma reports Q3 2026 total revenue of $89.0 million and ZUSDURI revenue of $68.0 million, while lowering JELMYTO full-year guidance. (Items: 2.02 Results of Operations and Financial Condition On November 4, 2026, UroGen Pharma Ltd, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 4, 2026, 13:08 UTC

Tickers: $URGN

Read the full article at SEC EDGAR

Part of the story InMode Reports Q3 2026 Financial Results with Stable Revenue and Reaffirmed Outlook (23 articles)

More Regulatory news

REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC
Future Vision II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
THUNDER MOUNTAIN GOLD INC - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
MiNK Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:49 UTC
SusGlobal Energy Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:42 UTC
Ideal Power Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:25 UTC
DIGI INTERNATIONAL INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:23 UTC
ZeroStack Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC